The Manufacturers Life Insurance Company Purchases 94,821 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

The Manufacturers Life Insurance Company boosted its position in Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating) by 21.6% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 533,745 shares of the life sciences company’s stock after buying an additional 94,821 shares during the period. The Manufacturers Life Insurance Company’s holdings in Integra LifeSciences were worth $22,609,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund boosted its position in shares of Integra LifeSciences by 1.1% in the third quarter. Oregon Public Employees Retirement Fund now owns 21,216 shares of the life sciences company’s stock valued at $899,000 after acquiring an additional 227 shares during the period. Great West Life Assurance Co. Can grew its position in shares of Integra LifeSciences by 4.8% during the 3rd quarter. Great West Life Assurance Co. Can now owns 46,556 shares of the life sciences company’s stock worth $1,969,000 after purchasing an additional 2,115 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of Integra LifeSciences by 23.6% during the third quarter. Jennison Associates LLC now owns 340,365 shares of the life sciences company’s stock worth $14,418,000 after purchasing an additional 64,963 shares during the period. Dupont Capital Management Corp acquired a new stake in shares of Integra LifeSciences in the third quarter valued at approximately $412,000. Finally, State of New Jersey Common Pension Fund D boosted its stake in shares of Integra LifeSciences by 26.3% in the third quarter. State of New Jersey Common Pension Fund D now owns 48,810 shares of the life sciences company’s stock valued at $2,068,000 after buying an additional 10,156 shares during the period. 87.60% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IART has been the subject of several analyst reports. TheStreet raised Integra LifeSciences from a “c+” rating to a “b-” rating in a report on Tuesday, December 27th. Citigroup boosted their price target on Integra LifeSciences from $50.00 to $60.00 and gave the company a “neutral” rating in a research note on Monday, December 12th. JMP Securities reduced their price objective on shares of Integra LifeSciences from $85.00 to $75.00 and set a “market outperform” rating on the stock in a research note on Thursday, October 27th. Morgan Stanley upped their price target on shares of Integra LifeSciences from $50.00 to $59.00 and gave the stock an “equal weight” rating in a report on Friday, January 6th. Finally, Jefferies Financial Group assumed coverage on shares of Integra LifeSciences in a research note on Tuesday, October 11th. They issued a “hold” rating and a $48.00 price objective on the stock. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $58.33.

Integra LifeSciences Stock Down 0.5 %

IART stock opened at $56.65 on Wednesday. The stock has a market capitalization of $4.73 billion, a P/E ratio of 27.50, a price-to-earnings-growth ratio of 1.60 and a beta of 1.14. The company has a current ratio of 3.93, a quick ratio of 2.91 and a debt-to-equity ratio of 0.86. The firm has a 50-day moving average price of $55.82 and a 200-day moving average price of $51.69. Integra LifeSciences Holdings Co. has a 12 month low of $40.67 and a 12 month high of $68.29.

Integra LifeSciences (NASDAQ:IARTGet Rating) last issued its quarterly earnings data on Wednesday, October 26th. The life sciences company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. The business had revenue of $385.19 million for the quarter, compared to analyst estimates of $377.79 million. Integra LifeSciences had a return on equity of 16.41% and a net margin of 11.05%. As a group, equities research analysts anticipate that Integra LifeSciences Holdings Co. will post 3.33 EPS for the current fiscal year.

About Integra LifeSciences

(Get Rating)

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company’s neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care, such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment, and the precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices.

Featured Articles

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating).

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.